Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, has emerged from stealth and launched. Simultaneously, it has announced its acquisition of Landmark Bio, a cell and gene therapy manufacturing company specializing in translational research, process development, and manufacturing technologies.

As a part of Artis, Landmark Bio will continue to operate as a distinct entity, focused on accelerating therapeutic development from preclinical through commercialization. Landmark Bio has developed significant scientific and technical capabilities that aim to remove bottlenecks and increase speed-to-clinic for developers of advanced therapies. Since 2021, Landmark Bio has delivered numerous successes for its partners, enabling the advancement of complex cell and gene therapies from bench to clinic.

“Joining Artis BioSolutions marks an exciting new chapter for Landmark Bio. Together, we will stay true to our mission as we scale our operations to bring breakthrough therapies to more patients,” said Ran Zheng, CEO of Landmark Bio.

With the acquisition of Landmark Bio, Artis BioSolutions is well-positioned as a premiere CDMO for advanced therapy developers looking for end-to-end capabilities within the fast-growing category of advanced therapies. From critical materials to technologies and manufacturing experience, Artis aims to support multiple modalities and enable shorter project timelines, lower manufacturing costs, high product quality, efficient supply chain management and the best customer experience.

Artis BioSolutions is led by CEO Brian Neel and CSO Mike Houston, two leaders with deep expertise in deploying best-in-class systems and technologies in the CDMO and broader therapeutics space. Combined with the Landmark Bio leadership team, the leadership at Artis offers strong expertise in translational sciences and clinical research and development.

“Advanced therapies will continue to be a driving force of innovation in the biopharma ecosystem, and we believe the industry is at an inflection point in advancing and developing the critical processes and the manufacturing of these therapies,” said Brian Neel, CEO of Artis BioSolutions. “Landmark Bio has a proven track record of leading advanced therapies through clinical development, and we are excited to build on this foundation with the support of Oak HC/FT.”

Initial funding for Artis is provided by Oak HC/FT. Artis will use this funding to further build out its services and technology platform and fuel future growth.

More Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.